Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN: Ranibizumab in CNV secondary to AMD
NCT00331864Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Primary completion
- Apr 2008
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Novartis. Started Apr 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00331864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331864.